Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

  1. Musolino, A.
  2. Campone, M.
  3. Neven, P.
  4. Denduluri, N.
  5. Barrios, C.H.
  6. Cortes, J.
  7. Blackwell, K.
  8. Soliman, H.
  9. Kahan, Z.
  10. Bonnefoi, H.
  11. Squires, M.
  12. Zhang, Y.
  13. Deudon, S.
  14. Shi, M.M.
  15. André, F.
Revue:
Breast Cancer Research

ISSN: 1465-542X,  1465-5411

Année de publication: 2017

Volumen: 19

Número: 1

Type: Article

DOI: 10.1186/S13058-017-0807-8 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus